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Richard J. JonesHistorically, graft-versus-host disease (GVHD),
particularly in the setting of HLA disparity, has con-
strained the applicability and availability of allogeneic
blood or marrow transplantation (BMT). In fact, the
search for appropriate alternative donors on behalf of
the many potential BMT recipients lacking matched
donors could be considered the ‘‘holy grail’’ of the
BMT field. Even when a match can be found, National
MarrowDonor Program data indicate that a median of
4months is required to complete searches that result in
BMT [1]. Thus, some patients will succumb to disease
while awaiting identification of a suitable HLA-
matched donor.
Given that more than 95% of patients will have
a HLA-haploidentical related donor (ie, parent, sib-
ling, or child), the ability to expeditiously and safely
use such donors would open up allogeneic BMT to vir-
tually all who might benefit. Haploidentical related
BMT would be especially useful for certain ethnic
groups, like African Americans, in whom finding
a matched unrelated donor has been problematic.
Until recently, however, mortality rates exceeding
50% from severe GVHD [2] have steered most centers
away from the use of haploidentical related donors.
Early preclinical and clinical allogeneic BMT
studies exclusively used total body irradiation (TBI)
because of its dual anticancer and immunosuppressive
properties. Because of limited access to facilities capa-
ble of providing TBI in the 1960s, as well as toxicity
concerns, Santos and Owens [3] explored potential
new BMT conditioning agents by evaluating the im-
munosuppressive properties of the anticancer agents
known at the time. They found cyclophosphamide
(Cy) to be the most immunosuppressive, and accord-
ingly developed it as a replacement for TBI [3]. Santos
and Owens also found that Cy administered at highThe Sidney Kimmel Comprehensive Cancer Center,
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effective in preventing alloreactivity in mice [4]. How-
ever, based on concerns that high-dose Cy given after
BMT might damage transplanted hematopoietic stem
cells (HSCs), the clinical trials that arose from these
preclinical studies actually used low-dose Cy as
GVHD prophylaxis. A randomized trial eventually
showed that cyclosporine was significantly better
than low-dose Cy for GVHD prophylaxis [5].
Subsequently, laboratory and corroborating clini-
cal data demonstrated that HSCs are resistant to
high-dose Cy [6]. HSCs express high levels of aldehyde
dehydrogenase 1 (ALDH1), the body’s primary means
of inactivating Cy, whereas lymphocytes generally ex-
press low levels [6]. The primary function of ALDH1,
also known as retinaldehyde dehydrogenase, is the bio-
synthesis of retinoic acid, which is required for the
growth and differentiation of HSCs and other highly
proliferative cells. ALDH1 actually inactivates Cy by
serendipity, through oxidation of the active metabolic
aldehyde intermediate aldophosphamide to the inac-
tive carboxylic acid carboxyphosphamide [6]. The suc-
cess of high-dose Cy without HSC rescue as treatment
for aplastic anemia and other autoimmune diseases [7]
provided further proof of its potent immunosuppres-
sive but HSC-sparing properties.
This laboratory and clinical evidence ofHSC resis-
tance to Cy led to the reconsideration of Cy as GVHD
prophylaxis, but this time at the high doses Santos and
Owens [4] found to be most effective in animal models
but were unwilling to test clinically. High-dose Cy
given early after BMT was again shown to effectively
prevent alloreactivity (GVHD and graft rejection)
and to spare HSCs, allowing successful mismatched-
donor BMT in mice [8]. Translational clinical trials
based on these preclinical studies showed that haploi-
dentical related BMT using posttransplantation Cy
(PTCy) produced outcomes similar to those seen
with HLA-matched BMT [9]. A national multi-
institutional clinical trial through the Blood and
Marrow Transplant Clinical Trials Network (BMT
CTN) confirmed the safety and effectiveness of hap-
loidentical BMT using PTCy [10].
Along with controlling haploidentical alloreactiv-
ity, PTCy is associated with excellent immune recon-
stitution and a low incidence of severe opportunistic
infections. The timing of PTCy administration1771
1772 Biol Blood Marrow Transplant 18:1771-1775, 2012R. J. Jonesappears to contribute to the drug’s selectivity toward
alloreactive T cells. Early after allogeneic BMT,
both donor and host alloreactive T cells are maximally
activated and proliferative, whereas T cells specific for
infectious agents are quiescent and thus less sensitive
to Cy-mediated cytotoxicity. Recent data demonstrate
that memory lymphocytes, like other cells with sub-
stantial proliferative capacity, also highly express
ALDH1 and thus are relatively resistant to Cy; these
Cy-resistant cells undoubtedly also contribute to the
favorable immune reconstitution seen after PTCy
therapy.
Allograft T cell depletion (TCD) also can limit
GVHD after haploidentical related BMT. Although
success with this approach has been reported in chil-
dren, most trials in adults have been associated with
relatively high nonrelapse mortality rates, related pri-
marily to slow immunologic reconstitution and infec-
tious complications [11].
In this issue of Biology of Blood and Marrow Trans-
plantation, Ciurea et al. [12] report the first direct com-
parison of TCD and PTCy for haploidentical related
BMT. In a retrospective analysis of 2 cohorts of haploi-
dentical BMT recipients treated at the University of
Texas M.D. Anderson Cancer Center using the same
conditioning regimen, PTCy produced statistically su-
perior actuarial overall survival and progression-free
survival compared with TCD. Although both ap-
proaches were associated with low rates of GVHD,
PTCy demonstrated significantly improved immune
reconstitution and lower nonrelapse mortality, pre-
dominately because of fewer infectious deaths.
In contrast to PTCy, TCD shows no selectivity to-
ward alloreactive T cells, also eliminating T cells reac-
tive against infectious agents, as well as memory
T cells. Thus, adequate functional immune reconstitu-
tion after TCD can develop in children and young
adults from the thymic output of na€ıve T cells, but
not in older adults (with thymic involution), who rely
predominately on the peripheral expansion of memory
T cells [13]. Transplantation with another alternative
donor source, unrelated umbilical cord blood, also
produces excellent results in children and young
adults. However, immune reconstitution and infec-
tious complications have been of concern in older
adults undergoing transplantation with these products,
which are similarly deficient in memory T cells [13]. A
randomized trial comparing unrelated umbilical cord
blood and haploidentical related transplantation in
adults lacking matched donors is currently underway
through the BMT CTN. Regardless of the outcome
of this BMTCTN trial, however, the article by Ciureaet al. provides further evidence that essentially all pa-
tients, even those without HLA-matched donors, can
now safely and effectively undergo BMT.ACKNOWLEDGMENT
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